Anti-BIRC7 (aa 264-280) polyclonal antibody

Name: Anti-BIRC7 (aa 264-280) polyclonal antibody
SKU: DPAB-L20684
Rating: 5 (1 reviews)

Rabbit anti-Human BIRC7 (aa 264-280) polyclonal antibody for IHC

Write a review

COA

SDS

Datasheet

Summary

Specifications

Antibody Isotype

IgG

Species Reactivity

Human

Immunogen

a synthetic peptide corresponding to amino acids 264-280 of the short form and 281-298 of the long form of human Livin. This sequence is identical between a and b forms of the Livin proteins.

Conjugate

Unconjugated

Target

Alternative Names

BIRC7; baculoviral IAP repeat containing 7; KIAP; LIVIN; MLIAP; RNF50; ML-IAP; baculoviral IAP repeat-containing protein 7; RING finger protein 50; livin inhibitor of apoptosis; kidney inhibitor of apoptosis protein; melanoma inhibitor of apoptosis protei

Entrez Gene ID

79444

UniProt ID

Q96CA5

Product Background

Antigen Description

This gene encodes a member of the inhibitor of apoptosis protein (IAP) family, and contains a single copy of a baculovirus IAP repeat (BIR) as well as a RING-type zinc finger domain. The BIR domain is essential for inhibitory activity and interacts with caspases, while the RING finger domain sometimes enhances antiapoptotic activity but does not inhibit apoptosis alone. Elevated levels of the encoded protein may be associated with cancer progression and play a role in chemotherapy sensitivity. Alternative splicing results in multiple transcript variants [provided by RefSeq, Jul 2013]

Pathway

Apoptosis; Apoptosis Modulation and Signaling; Pathways in cancer; Small cell lung cancer; Toxoplasmosis; Ubiquitin mediated proteolysis

Citations

Have you cited DPAB-L20684 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Peptides in common bean fractions inhibit human colorectal cancer cells

FOOD CHEMISTRY

Authors: Luna Vital, Diego A.; de Mejia, Elvira Gonzalez; Dia, Vermont P.; Loarca-Pina, Guadalupe

Abstract

The aim of this study was to characterize peptides present in common bean non-digestible fractions (NDF) produced after enzymatic digestion and determine their antiproliferative action on human colorectal cancer cells. Five NDF peptides represented 70% of total protein (GLTSK, LSGNK, GEGSGA, MPACGSS and MTEEY) with antiproliferative activity on human colon cancer cells. Based on the antiproliferative effect, HCT116 cell line was most sensitive to bean Azufrado Higuera (IC50=0.53 mg/ml) and RKO to Bayo Madero (IC50=0.51 mg/ml) peptide extracts. Both cultivars increased significantly (p < 0.05) the expression of p53 in HCT116 by 76% and 68%, respectively. Azufrado Higuera modified the expression of cell cycle regulation proteins p21 and cyclin B1. Bayo Madero modified the expression of mitochondrial activated apoptotic proteins BAD, cytC, c-casp3, Survivin, BIRC7. Results suggest that peptides present in common bean NDF contributed to the antiproliferative effect on human colorectal cancer cells by modifying molecules involved in either cell cycle arrest or apoptosis. (C) 2014 Elsevier Ltd. All rights reserved.

Expression of inhibitor of apoptosis protein (IAP) livin/BIRC7 in acute leukemia in adults: Correlation with prognostic factors and outcome

LEUKEMIA RESEARCH

Authors: El-Mesallamy, Hala O.; Hegab, Hany M.; Kamal, Amany M.

Abstract

The clinical relevance of livin/BIRC7 expression is still controversial in different types of malignancies, therefore this study was designed to evaluate the gene expression of livin in Egyptian adult AML and ALL. Livin expression level was higher in patients with unfavorable prognostic factors at diagnosis in both ALL (p = 0.002) and AML (p = 0.042) and its level was negatively correlated with event free survival (EFS) and overall survival (OS) in both ALL (p < 0.001for both) and AML (p = 0.001 and 0.023 respectively). This study suggests that livin expression is a novel prognostic marker in adult acute leukemia and thus needs to be incorporated into the patient stratification and treatment protocols. (C) 2011 Elsevier Ltd. All rights reserved.